Letter to the EditorScreening of group O platelet donors for high-titer ABO antibodies- limitations, feasibility, and future
Section snippets
Absence of a standard method of titration
Though erythrocytes agglutination technique is considered as the ‘gold-standard’ for ABO antibodies titration, a wide variation in the measurement of the ABO antibody titer has been observed among different blood centers due to the absence of a standard method of titration. Considering the low reproducibility and high subjective variation of conventional tube technique (CTT), most of the laboratories have started to use highly sensitive automated platforms using the micro-column agglutination
Lack of consensus to define critical titers
It is extremely difficult to reach a consensus to define the exact critical titres for ABO antibodies in group O platelet donors because pooling of tests results by performing a meta-analysis is not possible in this case as multiple methods are being followed by different centers for anti-A/-B titration. Furthermore, the complexity is increased by several folds as the tests of centers differ in almost every detail, including the use of donor plasma or serum, the medium used for dilution,
Unpredictable clinical implications
At present approximately 19 % of platelet transfusions in the United States are minor ABO incompatible [8]. Recently the International Society of blood Transfusion forum has also reported similar results by collecting the responses from 15 centers across the globe with a wider geographical location [9]. Whereas the US Food and Drug Administration data from 2007 to 2017 has reported only 6 fatalities due to the hemolysis from minor ABO incompatible platelet transfusions [10]. Clinically
Logistic problems
In most of the blood centers the choice of ABO-compatible or ABO-incompatible platelets is often driven by logistic considerations, i.e., to ensure the supply. As discussed before, if a significant percentage of group O donors become ineligible for non-O group recipients due to the presence of high-titer isoagglutinins; managing the platelet inventory becomes a great challenge. In addition, there is no consensus or standard policy in place to permanently exclude group O platelet donors with
Conclusion
Hemolytic reactions occur most commonly if the anti-A/-B antibody titer exceeds 1:64 to 1:100 in saline (IgM) or 1:256 to 1:400 with antiglobulin reagent (IgG), however hemolysis have been reported in transfusions with low-titer units also [17]. Therefore, the hemolytic activity is not restricted to titer alone rather it is much more complex than what we apparently perceive. The complement-activating property of IgM or IgG is identified as one of the major determining factors to define the
References (21)
ABO isohemagglutinin titration or hemolysin test: what should we do to reduce the risk of passive hemolysis?
Rev Bras Hematol Hemoter
(2015)- et al.
ABH-glycan microarray characterizes ABO subtype antibodies: fine specificity of immune tolerance after ABO-incompatible transplantation
Am J Transplant
(2016) - et al.
Better ABO antibody detection tools to facilitate ABO-incompatible transplant risk assessment
J Heart Lung Transplant
(2020) - et al.
N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and fc fusionproteins
Eur J Pharm Biopharm
(2016) - et al.
A prominent lack of IgG1-fc fucosylation of platelet alloantibodies in pregnancy
Blood
(2014) - et al.
High titers of anti-A1 and anti-B antibodies among Peruvian group O platelet donors
Transfus Apher Sci
(2021) - et al.
Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration
Transfusion
(2013) - et al.
Comparative evaluation of the conventional tube test and column agglutination technology for ABO antibody titration in healthy individuals: a report from India
Immunohematology
(2021) - et al.
A standardized kodecyte method to quantify ABO antibodies in undiluted plasma of patients before ABO-incompatible kidney transplantation
Transfusion
(2019) - et al.
NHLBI Recipient Epidemiology and Donor Evaluation (REDS-III) Study. The epidemiology of platelet transfusions: an analysis of platelet uses at 12 US hospitals
Transfusion
(2020)
Cited by (1)
High Titer Antibodies Demonstrating Prozone in Two Repeat Blood Donors
2023, Indian Journal of Hematology and Blood Transfusion